Keros Therapeutics Inc (NASDAQ: KROS) kicked off on Tuesday, down -1.17% from the previous trading day, before settling in for the closing price of $11.13. Over the past 52 weeks, KROS has traded in a range of $9.77-$73.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -50.00% over the last five years. While this was happening, its average annual earnings per share was recorded 0.22%. With a float of $32.86 million, this company’s outstanding shares have now reached $39.26 million.
The firm has a total of 136 workers. Let’s measure their productivity. In terms of profitability, gross margin is -27.5%, operating margin of -31341.63%, and the pretax margin is -27890.94%.
Keros Therapeutics Inc (KROS) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Keros Therapeutics Inc is 18.87%, while institutional ownership is 83.08%. The most recent insider transaction that took place on Aug 13 ’24, was worth 11,002,500. In this transaction Director of this company sold 250,000 shares at a rate of $44.01, taking the stock ownership to the 119,522 shares. Before that another transaction happened on Aug 13 ’24, when Company’s Director sold 250,000 for $44.01, making the entire transaction worth $11,002,500. This insider now owns 119,522 shares in total.
Keros Therapeutics Inc (KROS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.74% during the next five years compared to -111.11% drop over the previous five years of trading.
Keros Therapeutics Inc (NASDAQ: KROS) Trading Performance Indicators
Take a look at Keros Therapeutics Inc’s (KROS) current performance indicators. Last quarter, stock had a quick ratio of 19.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 685.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.21, a number that is poised to hit -1.36 in the next quarter and is forecasted to reach -4.83 in one year’s time.
Technical Analysis of Keros Therapeutics Inc (KROS)
Analysing the last 5-days average volume posted by the [Keros Therapeutics Inc, KROS], we can find that recorded value of 1.07 million was lower than the volume posted last year of 2.03 million. As of the previous 9 days, the stock’s Stochastic %D was 13.63%. Additionally, its Average True Range was 1.28.
During the past 100 days, Keros Therapeutics Inc’s (KROS) raw stochastic average was set at 1.96%, which indicates a significant decrease from 43.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.43% in the past 14 days, which was lower than the 215.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.36, while its 200-day Moving Average is $46.73. Now, the first resistance to watch is $11.25. This is followed by the second major resistance level at $11.49. The third major resistance level sits at $11.63. If the price goes on to break the first support level at $10.87, it is likely to go to the next support level at $10.73. Now, if the price goes above the second support level, the third support stands at $10.49.
Keros Therapeutics Inc (NASDAQ: KROS) Key Stats
The company with the Market Capitalisation of 445.58 million has total of 40,507K Shares Outstanding. Its annual sales at the moment are 150 K in contrast with the sum of -152,990 K annual income. Company’s last quarter sales were recorded 390 K and last quarter income was -52,960 K.
